1. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004;50:937-943.

2. Rott KT, Agudelo CA. Gout. JAMA 2003;289:2857-2860.

3. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: Is the incidence rising? J Rheumatol 2002;29:2403-2406.

4. Cassetta M, Gorevic PD. Crystal arthritis: Gout and pseudogout in the geriatric patient. Geriatrics 2004;59:25-31.

5. Agudelo CA, Wise CM. Crystal-associated arthritis. Clin Geriatr Med 1998;14:495-513.

Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-1190.

Cardona F, Tinahones FJ, Collantes E, et al. Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout. Ann Rheum Dis 2005;64:85-88.

Shekarriz B, Stoller ML. Uric acid nephrolithiasis: Current concepts and controversies. J Urol 2002;168(4 Pt 1):1307-1314.

Terkeltaub RA. Gout. N Engl J Med 2003;349:1647-1655.

Schumacher Jr HR. Crystal induced arthritis: An overview. Am J Med 1996;100 (Suppl 2A):46-52.

Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-1324.

Schlesinger N, Baker DK, Beutler AM, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002;29:331-334.

Schlesinger N. Management of acute and chronic gouty arthritis. Drugs 2004;64:2399-2416.

Conaghan PG, Day RO. Risks and benefits of drugs used in the management and prevention of gout. Drug Saf 1994;11:252-258.

Smallwood JI, Malawista SE. Colchicine, crystals, and neutrophils tyrosine phosphorylation. J Clin Invest 1993;92:1602-1603.

Wallace SL, Singer JZ, Duncan GJ, et al. Renal function predicts colchicine toxicity: Guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991;18:264-269.

Dixon AJ, Wall GC. Probable colchicine-induced neutropenia not related to intentional overdose. Ann Pharmacother 2001;35:192-195.

Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med 2002;22:385-387.

Kim KY, Ralph Schumacher H, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-1617.

Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet 2008;371:1854-1860.

Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994;21:1325-1327.

de Klerk E, van der Heijde D, Landewe R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54.

Pal B, Foxall M, Dysart T, et al. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000;19:21-25.

Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-983.

Khoo BP, Leow YH. A review of inpatients with adverse drug reactions to allop-urinol. Singapore Med J 2000;41:156-160.

Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: A review. Ann Pharmacother 1993;27:337-343.

Bardin T. Current Management of gout in patients unresponsive or allergic to al-lopurinol. Joint Bone Spine 2004;71:481-485.

Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001;44:231-238.

Becker MA, Schumacher HR Jr., Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-2461.

Takahashi S, Moriwaki Y, Yamamoto T, et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003;62: 572-575.

Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ Jr. Tumor lysis syndrome. Semin Thromb Hemost 2007;33:397-407.

Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 2008;26:2767-2778.

Holdsworth MT, Nguyen P. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. Am J Health Syst Pharm 2003;60:2213-2222.

34. Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci 2007;4:83-93.



Thank you for deciding to learn more about the disorder, Osteoarthritis. Inside these pages, you will learn what it is, who is most at risk for developing it, what causes it, and some treatment plans to help those that do have it feel better. While there is no definitive “cure” for Osteoarthritis, there are ways in which individuals can improve their quality of life and change the discomfort level to one that can be tolerated on a daily basis.

Get My Free Ebook

Post a comment